Opioid Use Disorder Market, by Drug Type (Buprenorphine, Methadone, Naltrexone, and Others), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) and by Region (North America, Latin

Opioid Use Disorder Market, by Drug Type (Buprenorphine, Methadone, Naltrexone, and Others), by Route of Administration (Oral and Parenteral), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Opioids, used medically for pain relief, have analgesic and central nervous system depressant effects as well as the potential to cause euphoria. Opioid use disorder (OUD) can involve misuse of prescribed opioid medications, use of diverted opioid medications, or use of illicitly obtained heroin. OUD is typically a chronic, relapsing illness, associated with significantly increased rates of morbidity and mortality. In patients with OUD who have achieved abstinence through medically supervised withdrawal or by other means, maintenance treatment aims to prevent relapse. Options for long-term maintenance treatment include an opioid agonist (i.e., methadone or buprenorphine), an opioid antagonist (naltrexone), or non-medication, abstinence-based treatment.
Market Dynamics
Increasing incidences of pain associated with chronic diseases such as cancer, rising cases of opioid addiction, and increasing adoption of inorganic growth strategies by key players in order to expand their product portfolio in the global opioid use disorder market. The general population nowadays suffers from a wide range of chronic and severe health conditions, such as pain arising from injuries or cancer. They often result in chronic pain and in such cases, patients are given painkillers, especially opioids. While they help in lowering pain, they can cause addiction among patients. The abrupt discontinuation or higher dependency on these drugs leads to withdrawal symptoms. This further increases the chances of fatal consequences, such as deaths.
For instance, The American Psychiatric Association (APA), stated that approximately 72,000 Americans died due to opioid overdose in 2017. These factors are likely to drive the opioid use disorder market growth in the near future.
Key features of the study:
This report provides in-depth analysis of the global opioid use disorder market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global opioid use disorder market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Indivior PLC, Alkermes, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, BioDelivery Sciences International Inc., Viatris Inc., Pfizer, Inc., Hikma Pharmaceuticals PLC, and Camurus
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global opioid use disorder market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global opioid use disorder market
Detailed Segmentation:
Global Opioid Use Disorder Market, By Drug Type:
Buprenorphine
Methadone
Naltrexone
Others
Global Opioid Use Disorder Market, By Route of Administration:
Oral
Parenteral
Global Opioid Use Disorder Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Opioid Use Disorder Market, By Region:
North America
By Drug Type
Buprenorphine
Methadone
Naltrexone
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Type
Buprenorphine
Methadone
Naltrexone
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type
Buprenorphine
Methadone
Naltrexone
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
By Drug Type
Buprenorphine
Methadone
Naltrexone
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
By Drug Type
Buprenorphine
Methadone
Naltrexone
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
GCC
Israel
Rest of Middle East
Africa
By Drug Type
Buprenorphine
Methadone
Naltrexone
Others
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country
South Africa
Central Africa
North Africa
Company Profiles
Indivior PLC *
Company Overview
Material Portfolio
Financial Performance
Key Highlights
Market Strategies
Alkermes
Orexo AB
Titan Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd.
Mallinckrodt Pharmaceuticals
BioDelivery Sciences International Inc.
Viatris Inc.
Pfizer, Inc.
Hikma Pharmaceuticals PLC
Camurus
“*” marked represents similar segmentation in other categories in the respective section.